Showing results (661-670 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. Oncology|February 25, 2011
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation studyIrene M Ghobrial, Edie Weller, Ravi Vij, et al.
Blood|September 29, 2012
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasoneDavid I Lichter, Hadi Danaee, Michael D Pickard, et al.
Nature Cell Biology|October 22, 2021
Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myelomaJulia Frede, Praveen Anand, Noori Sotudeh, et al.
British Journal of Haematology|January 28, 2009
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guidelinePaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2012
Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidenceMaria T Di Martino, Emanuela Leone, Nicola Amodio, et al.
Nature Medicine|May 13, 2014
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancersFrancesca Cottini, Teru Hideshima, Chunxiao Xu, et al.
Cancer Cell|September 15, 2012
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistanceDharminder Chauhan, Ze Tian, Benjamin Nicholson, et al.
Lancet (London, England)|November 19, 2019
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 studyMichel Attal, Paul G Richardson, S Vincent Rajkumar, et al.
Blood|December 18, 2012
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomibPaul G Richardson, David Siegel, Rachid Baz, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 3, 2010
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone diseaseSonia Vallet, Siddhartha Mukherjee, Nileshwari Vaghela, et al.
Pageof 79